Background: Concentrations of tenofovir (TFV) in hair and tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) as measures of cumulative exposure have been primarily studied in younger, HIV-uninfected individuals taking preexposure HIV prophylaxis. Data on these measures among older HIV-infected individuals are limited.
INTRODUCTION
Tenofovir (TFV) concentrations in hair and tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) are used to measure cumulative exposure and adherence in studies that generally include younger, HIV-uninfected individuals taking tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for preexposure prophylaxis. [1] [2] [3] In this patient population, TFV concentrations in hair and TFV-DP in DBS are linearly related to cumulative TDF dosing, 4, 5 and these measures correlate with one another, indicating similar pharmacokinetic profiles. [6] [7] [8] To date, few studies have characterized TFV in hair or TFV-DP in DBS in an HIV-infected population, especially among older adults, who represent a growing segment of patients with HIV. Older age and corresponding physiological changes, such as graying hair, lower hematocrit (Hct), and reduced renal function, may alter concentrations of TFV in hair and TFV-DP in DBS. 9 The study objective was to characterize and compare concentrations of TFV in hair and TFV-DP in DBS in virally suppressed, HIV-infected adults from younger (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) and older ($60 years) age groups. The correlation between these measures and the clinical covariates associated with each exposure measure were also determined.
METHODS
This was a secondary, hypothesis-generating analysis performed in a study examining renal function over one year in virally suppressed (,48 copies/mL on 2 consecutive visits), HIV-infected adults aged either 18-35 years or 60 years and older with $1 year of consistent use of TDF-based antiretroviral therapy. All participants provided written informed consent before entry. The study was approved by the local IRB and registered with ClinicalTrials.gov (NCT02304263). Participants completed 2 study visits, separated by 1 year. Blood and hair samples were collected at each study visit. Creatinine clearance (CrCl) was calculated at each visit using the Cockcroft-Gault equation. 10 For the DBS samples, 25 mL of whole blood was spotted onto 903 Protein Saver cards (Whatman/GE Healthcare, Piscataway, NJ), allowed to dry for $2 hours (up to overnight), placed in plastic bags with humidity indicators and desiccants, and stored in a sample box at 280°C until analysis. 11 Approximately 100 strands of hair ($1 inch) were cut from the occipital region of the scalp 12 ; hair color was noted by the laboratory on analysis. Validated liquid chromatography/tandem mass spectrometry methods were used to quantify TFV concentrations in plasma, 6,13 the proximal 1.5 cm of hair, and TFV-DP from a 3-mm DBS punch. 4, 14 Participants were included in the study if they were virologically suppressed through electronic medical chart review indicating viral suppression (,48 copies/mL) on 2 consecutive clinic visits preceding visit 1. Eligibility for visit 2 required viral suppression at one clinic appointment preceding the second visit. In addition, a Visual Analog Scale (VAS) for self-reported adherence over the past 3 months, 30 days, and 3 days was completed by the participants at both visits.
Statistical Analysis
Predictors in the multivariable longitudinal regression models included age group, CrCl, completely gray hair color (yes/no) (hair model), and Hct (DBS model). Study visit was not considered because subjects were on stable treatment. TFV and TFV-DP concentrations were natural log transformed before analysis. To reduce skewness, a constant [the lower limit of quantification for the assay (0.002 ng/mL)] was added to TFV concentrations in hair before log transformation, and analysis was performed on the outcome [ln(0.002 + TFV in hair)], consistent with previous studies involving TFV in hair. 15 This approach is necessary as log transformations tend to exaggerate differences between very small values, which are clinically comparable. 16, 17 Results represent a percent change in TFV levels by covariate after adjusting for all other variables in the model. A repeated-measures multivariable regression model using data from both study visits (when available) was used to assess relationships between drug concentrations and participant characteristics. A Pearson correlation between TFV-DP in DBS and TFV in hair was calculated at visit 1 only, given some loss to follow-up and to meet independence assumptions. All analyses were complete in R/SAS, versions 3.3.3/9.4, respectively. As this was a secondary, hypothesisgenerating analysis, no adjustment was made for multiple comparisons. 18, 19 
RESULTS

Study Participants
Visits 1 and 2 included 45 and 34 participants, respectively; of those not included in visit 2, 9 were from the 18-to 35-year-old group [7 were no longer eligible (5 switched to non-TDF-based ART, 1 moved out of state, and 1 stopped taking ART), 1 lost to follow-up, and 1 death] and 2 were from the 60-year and older group (1 lost eligibility because of medical complications and 1 lost to follow-up). Table 1 shows the baseline demographics of all study participants. The number of participants taking a pharmacokinetic "booster" (ritonavir or cobicistat) as part of their antiretroviral regimen did not differ between the cohorts. As expected, mean (SD) CrCl was significantly lower among the older participants. Baseline TFV concentrations [geometric mean (95% CI)] in plasma did not differ significantly between the younger [103 ng/mL (73, 144)] and older [92 ng/mL (40, 210)] cohorts (P = 0.65). One older participant had a plasma concentration below the level of quantification for which one half of the lower limit of quantification (LLOQ was 10 ng/ mL 13 ) was imputed. Overall, mean (SD) self-reported adherence using VAS over the previous 3 months, 30 days, and 3 days was 97% (5), 98% (4), and 99% (6) for visit 1% and 97% (4), 95% (16) , and 97% (16) for visit 2, respectively, with no significant differences between the younger and older groups (all P . 0.290). These VAS and plasma quantitation values were consistent and indicative of high adherence.
Factors Associated With TFV Concentrations in Hair
Thirty-nine participants had sufficient hair ($1 inch) to provide a sample. Nineteen were 60-year and older, 6 had completely gray hair (all from the older cohort), 35 were men, 
Factors Associated With TFV-DP Concentrations in DBS
Forty-five participants provided at least one blood sample used in the DBS analysis. One DBS sample from visit 1 was excluded because of elevated TFV-DP concentrations resulting from a drug interaction with ledipasvir/ sofosbuvir for which interpretation benchmarks are available. 20 Unadjusted TFV-DP concentrations in DBS at baseline were not significantly higher in older versus younger participants [9.0% (29.5% to 31.4%; P = 0.36)]. As with hair, CrCl was significantly associated with TFV-DP in DBS in univariate analysis, with a 6.2% (0.6% to 12.1%) increase for every 20-mL/min decrease in CrCl (P = 0.031). Hct was also a significant univariate predictor with a 3.3% (0.2% to 6.5%) TFV-DP increase (P = 0.04) for every 1% increase in Hct. After adjustment for age and Hct in the multivariable model, the effect of CrCl on TFV-DP levels was attenuated but still showed a trend toward the association of higher TFV-DP concentrations with decreased renal function: TFV-DP concentrations were 5.7% (20.2% to 11.9) higher for every 20-mL/min decrease in CrCl (P = 0.057). Older age was not predictive of higher concentrations in DBS [4.0% (214.1% to 25.9%); P = 0.68] after adjustment for CrCl and Hct. The Hct estimate (95% CI) did not change from the unadjusted model.
TFV in Hair and TFV-DP in DBS
Thirty-nine participants provided both DBS and hair samples at visit 1. As shown in Figure 1 , concentrations of TFV-DP in DBS and TFV in hair were significantly, but moderately, correlated [Pearson correlation: 0.50, (95% CI: 0.21 to 0.71); P = 0.001].
DISCUSSION
This study evaluated TFV in hair and TFV-DP in DBS in a unique population of virologically suppressed older (60 years and older) and younger (18-35 years) HIV-infected individuals. Using adjusted multivariable models, we found an inverse relationship between creatinine clearance and drug concentrations (TFV and TFV-DP) in hair and DBS, respectively. Furthermore, we found significant increases in TFV-DP in DBS with increasing Hct (P = 0.04) in adjusted analyses. We did not find a relationship between age (or hair color) and drug concentrations in either matrix after adjusting for renal function. Given a small number of women (N = 4), sex was not considered as a predictor and weight was collinear with other predictors. Last, we found a moderate correlation between TFV in hair and TFV-DP in DBS, suggesting similarities in the pharmacokinetics of these measures among younger and older individuals. Taken together, these data suggest that either hair or DBS measures could be used to measure exposure to TFV-based regimens in older individuals and that the association of renal function on these exposure measures requires study in a larger cohort.
The association between Hct among older individuals and TFV-DP concentrations in DBS was not unexpected. A similar association was observed in validation studies among HIV-uninfected volunteers, 11, 14 where TFV-DP values for Hct values at the ends of the normal range (35% and 50%) were within 15% of TFV-DP values in the middle of the Hct range. 11 As baseline Hct was similar between age groups (Table 1) , with similar estimates in the adjusted and unadjusted models, it does not seem to be a confounder in the relationship between age and TFV-DP concentration. In terms of hair color, our study included HIV-infected adults aged 60 years and older, 6 of whom had completely gray hair. Differences in hair color result from variable amounts and combinations of melanin in the hair cortex, and hair graying is characterized by loss of pigment in the hair shaft. 21 In our study, however, hair color was not associated with TFV hair concentrations in adjusted analyses.
Our results indicate that slower renal clearance, regardless of age, was associated with higher concentrations of TFV in hair and a trend toward higher TFV-DP in DBS. Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion 22 ; higher plasma concentrations of drug are thereby expected with decreased kidney function. 23 In our study, all but 3 calculated CrCl values, including data from both study visits, were above 50 mL/min, suggesting that elevated drug concentrations may be occurring in individuals with relatively healthy kidneys, which has been previously observed. 23 Although renal decline has been reported in individuals between the ages of 35 and 60 years old, 9 our study did not include this age group, so results may not characterize the impact of renal function for this demographic. Given that both TFV in hair and TFV-DP in DBS measure cumulative drug exposure, these drug concentrations may provide quantitative evidence of slower renal clearance in older and younger individuals. Of note, TFV exposure can also influence renal function, and one limitation of our analyses is that we could not determine the directionality of the association between drug concentrations and renal function. A larger longitudinal study is needed to determine the relationship between drug levels in hair and DBS and renal function among older individuals.
Finally, TFV in hair and TFV-DP in DBS have both been used to assess adherence to TDF-based regimens. In this study, both measures (as well as VAS and plasma drug detection) indicated near 100% adherence in both age groups based on previous directly observed therapy studies. 4, 5 Adherence to antiretroviral therapy continues to be the most significant predictor of clinical outcomes in prevention and treatment of HIV. This study indicates that both measures could be useful as adherence assessments in older HIVinfected individuals on treatment.
